KROS
Keros Therapeutics, Inc.21.53
+0.30+1.41%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
655.93MP/E (TTM)
13.80Basic EPS (TTM)
1.56Dividend Yield
0%Recent Filings
8-K
Keros ALS trial deal, Phase 1 data
Keros Therapeutics inked a deal with Massachusetts General Hospital on March 9, 2026, to design a Phase 2 trial of rinvatercept in ALS patients via the HEALEY ALS MyMatch program. It also unveiled Phase 1 data at the MDA Conference, showing target engagement, muscle gains, fat loss, and bone density boosts in healthy volunteers—well-tolerated across doses. Phase 2 trials in DMD and ALS advance. Trial delays loom as a key risk.
10-K
FY2025 10-K filing
Keros Therapeutics filed its 10-K for FY2025 ended December 31, 2025, but provided no consolidated financial statements, revenue, profitability, or quarterly results in the excerpt. No GAAP totals, y/y deltas, or Q4 metrics appear. Exhibits detail director compensation policy updates and amendments to a Takeda license agreement from December 2024 through June 2025, plus an executive employment tweak. Cash position undisclosed. No guidance given. Clinical trial delays could stall momentum.
8-K
Profitable year, trials ahead
Keros Therapeutics swung to $87.0M net income for 2025, fueled by $205M license revenue from Takeda, yet R&D expenses dropped to $129.6M after shifting elritercept work. Cash fell to $287.4M amid share repurchases, funding operations into H1 2028. Phase 2 rinvatercept trials loom for DMD in Q2 2026. Leadership sharpened.
8-K
Keros updates rinvatercept pipeline
Keros Therapeutics updated its corporate presentation on March 4, 2026, highlighting rinvatercept (KER-065) progress for DMD and ALS. Phase 1 data showed increased muscle mass, bone density, and fat reduction; Phase 2 DMD trial starts Q2 2026. Elritercept deal with Takeda nets $200M upfront, over $1.1B milestones. Risks include clinical delays.
8-K
Newton joins Keros board
Keros Therapeutics appointed Charles Newton, ex-CFO of Lyell Immunopharma with deep healthcare finance expertise, to its board effective March 9, 2026, replacing Dr. Carl Gordon who resigned the same day without disagreements. Newton joins the Compensation and Audit Committees. His capital markets savvy bolsters oversight amid pipeline advances. Standard director pay includes $150,000 initial option and RSU grants.
AKRO
Akero Therapeutics, Inc.
54.65+0.00
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
EWTX
Edgewise Therapeutics, Inc.
22.77-1.17
GTBP
GT Biopharma, Inc.
0.72+0.09
KAPA
Kairos Pharma, Ltd.
0.74+0.00
KRRO
Korro Bio, Inc.
8.22+0.26
KZR
Kezar Life Sciences, Inc.
6.30+0.02
OMER
Omeros Corporation
8.77-0.43
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05